Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2019: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
The interplay between breast cancer cells and bone cells in bone marrow microenvironments play an important role in tumor progression through the secreting factors. Although extracellular vesicles (EVs) released from cancer cells have shown to regulate the many types of cancer progression, In this study, we explored the implications of bone metastatic breast cancer cell-derived EVs in the regulation of osteoblast differentiation and mineralization. Treatment of MC3T3-E1 and ST2 osteoblastic cells with mouse bone metastatic (4T1) mammary tumor cell-derived EVs (4T1-EV) inhibited mineralization, which associated with the decreased in the expression of ATF4 . 4T1-EV treatment attenuated the activation of ERK, JNK and p38MAPK phosphorylation in ST2 cells. Our results demonstrate the implication of 4T1-EV-mediated osteoblast maturation and mineralization through MAPK pathways.
|